All the Active Ingredient Drugs
Bisphosphonate. Zoledronic Acid 5 mg / 100 ml. SOL. FOR INFUS: 1 x 100 ml.
Single I.V. infus. 5 mg x 1 yr. See lit.
Tmt. Paget’s dis. of bone. Tmt. osteoporos.
post-menopaus. women, men at incr. risk
fracture, incl. recent low trauma hip
fracture. Tmt./prevent. glucocorticoidinduc.
osteoporos. Prevent. post
menopaus. osteoporos. in women when
biphosphonate ther. indicat.
C/I: Hypersens. to excips. or any
bisphosphonates, hypocalcem., pregn.,
lact., sev. ren. impair. (CLcr<35 mL/min).
Bisphosphonate. Zoledronic Acid 4 mg / 5 ml. VIAL: 5 ml. The 4 mg/5 mL concentr. should be further diluted with 100 mL 0.9% w/v NaCl or 5% w/v glucose sol. before infus. The final sol. for infus. should be given as an IV infus. of no less than 15 min.
Tmt. of hypercalcaem. of malig. (HCM): Hypercalcaem. of malignan. is defined as albumin correct. ser. calcium ≥12 mg/dL [3.0 mmol/L]). In adult and elderly pts. the recomm. dose is a single 4 mg infus. Pts. must be maintain. well hydrated prior to and follow. admin.
Multiple myeloma and bone metastases from solid tumors: In adult and elderl. pts. the recomm. dose is a 4 mg infus. given every 3- 4 wks. Pts. should also be admin. an oral calcium supplem. of 500 mg & 400 IU.
Tmt. of hypercalcaem. of malignan. Tmt. of pts. with multiple myeloma and pts. with document. bone metastases from solid tumors, in conjunct. with standard antineoplast. ther. Prostate cancer should have progressed after tmt. with at least one hormone. ther.
C/I: Hypersens. Lact.
